argenx SE (ARGX)
argenx SE at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
argenx SE (ARGX) is a Biotechnology company based in NL with a market capitalization of $51.7B. Revenue grew 89.6% year-over-year and the company generated $844.3M in free cash flow. This page tracks ARGX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
NL · 1.6K employees · IPO May 18, 2017
Valuation
Valuation & price
$805.13as of May 26, 2026· -13.4% vs 52w high
41.1
P/E ratio
Latest-FY diluted EPS
7.07
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$51.7B
Market cap
89.6%
Revenue growth (YoY)
89.2%
Gross margin
$844.3M
Free cash flow (USD)
-$4.4B
Net debt
Net cash position
2.4%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 6-K filingJun 23, 2026Filing
R&D Webinar Announcement
- 6-K filingJun 3, 2026Filing
New Efgartigimod Data Presented
- 6-K filingMay 11, 2026Filing
FDA Approval Announcement
- Quarterly reportMay 7, 2026Filing
Quarterly Report Filed
- 6-K filingMay 6, 2026Filing
Management Change
- 6-K filingApr 20, 2026Filing
Data Presentation at AAN 2026
Questions
Frequently asked questions
What is argenx SE's market cap?
argenx SE (ARGX) has a market capitalization of $51.7B.
What is ARGX's P/E ratio?
ARGX trades at a price-to-earnings ratio of 41.1, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is ARGX's price-to-book (P/B) ratio?
ARGX trades at 7.07 times book value per share.
Are insiders buying ARGX stock?
SEC Form 4 filings show no open-market insider buys at argenx SE in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.